GoodRx (GDRX) Stock Forecast & Price Target

$4.56 -0.10 (-2.15%)

(As of 11/14/2024 ET)

GoodRx - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
1

Hold
4

Buy
10

Based on 15 Wall Street analysts who have issued ratings for GoodRx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, 4 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for GDRX.

Consensus Price Target

$8.86
94.24% Upside

According to the 15 analysts' twelve-month price targets for GoodRx, the average price target is $8.86. The highest price target for GDRX is $16.00, while the lowest price target for GDRX is $4.50. The average price target represents a forecasted upside of 94.24% from the current price of $4.56.

GDRX Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	9 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$8.86	$9.36	$9.36	$7.94
Forecasted Upside	94.24% Upside	35.22% Upside	30.50% Upside	52.64% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

GDRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GDRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GoodRx Stock vs. The Competition

Type	GoodRx	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	94.24% Upside	26,222.84% Upside	8.87% Upside
News Sentiment Rating	Neutral News See Recent GDRX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$10.00 ➝ $7.00	+51.84%
11/11/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$10.00 ➝ $6.00	+20.97%
8/16/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00	+42.45%
8/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$9.00 ➝ $8.50	+19.89%
8/9/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Ransom Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$10.00	+42.65%
6/10/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.50	+11.11%
Unveiled: NVIDIA’s "Secret Royalty" Program (Ad) Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip? Click Here to learn how to get in now >>>
5/16/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$14.00 ➝ $16.00	+95.36%
4/10/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sector Weight ➝ Overweight	$9.00	+33.53%
3/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$7.50 ➝ $10.00	+51.98%
3/1/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$6.50 ➝ $7.50	-3.72%
3/1/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$7.50 ➝ $8.00	+2.70%
3/1/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Overweight	$7.00 ➝ $10.00	+28.37%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$8.00	+25.39%
1/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Underperform	$8.00 ➝ $4.50	-32.84%
8/10/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$8.00 ➝ $10.00	+18.62%
8/10/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$6.00 ➝ $8.00	-5.10%
8/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$7.00 ➝ $8.00	-4.88%
8/10/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line ➝ In-Line	$7.00 ➝ $10.00	+25.94%
8/10/2023	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Simmons Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$9.50	+19.65%
11/16/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$6.50	+29.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:26 AM ET.

GDRX Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for GoodRx is $8.86, with a high forecast of $16.00 and a low forecast of $4.50.
: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There is currently 1 sell rating, 4 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GDRX shares.
: According to analysts, GoodRx's stock has a predicted upside of 94.24% based on their 12-month stock forecasts.
: GoodRx has been rated by research analysts at Barclays, and Citigroup in the past 90 days.
: Analysts like GoodRx less than other "medical" companies. The consensus rating score for GoodRx is 2.67 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GDRX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

This page (NASDAQ:GDRX) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GoodRx (GDRX) Stock Forecast & Price Target